ArticleJournal of bone oncology2026
MiRNA-based expression signatures in differential diagnosis of enchondroma and chondrosarcoma.
Article in Journal of bone oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The clinical and histological differentiation of benign enchondroma from malignant chondrosarcoma remains a major challenge. Due to their histological similarity, discrimination of enchondroma from low-grade chondrosarcoma G1/ACT particularly complicates accurate diagnosis. MicroRNAs (miRNAs) are promising biomarkers to identify chondrogenic tumors. Materials and methods: The expression of miR-138-5p, miR-181a-5p, miR-143-3p, and miR-145-5p was assessed by RT-qPCR in tissue samples, as well as in platelets and plasma from healthy donors and patients with enchondroma or chondrosarcoma. Results and discussion: In chondrogenic tumor tissue compared to adjacent non-tumor tissue the expression of miR-138-5p was significantly increased in enchondroma and low- grade chondrosarcoma G1/ACT, whereas miR-181a-5p expression revealed no significant difference. In contrast, miR-143-3p expression was significantly downregulated in enchondroma and high-grade chondrosarcoma G2 and G3, whereas miR-145-5p exhibited significant downregulation in low-grade chondrosarcoma G1/ACT and high-grade chondrosarcoma G2 relative to the corresponding adjacent non-tumorous tissue. Comparing expression of miR-138-5p, miR-181a-5p, miR-143-3p, and miR-145-5p in enchondroma to chondrosarcoma of different grades, miR-145-5p was significantly decreased in low-grade as well as in high-grade chondrosarcoma and significantly differentiated enchondroma from chondrosarcoma in tissue samples. Analysis in platelets of enchondroma and low-grade chondrosarcoma G1/ACT patients compared to healthy donors revealed no significant change in expression. However, in human plasma significant downregulation of miR-181a-5p and miR-143-3p in enchondroma and low-grade chondrosarcoma G1/ACT patients compared to healthy donors with corresponding ROC curves was demonstrated. Conclusion: While miR-138-5p and miR-143-3p show potential as tissue-based biomarkers for chondrogenic tumors, miR-145-5p appears to be particularly promising in differentiating enchondroma from chondrosarcoma of all grades. MiR-181a-5p and miR-143-3p exhibit diagnostic value in plasma. However, these findings are exploratory and larger, multicenter studies with independent validation cohorts are essential to confirm their clinical utility to establish robust diagnostic thresholds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.